Reata Pharmaceuticals, Inc.

(NASDAQ GM: RETA)

Rigrodsky Law, P.A. is investigating Reata Pharmaceuticals, Inc. (“Reata”) regarding possible breaches of fiduciary duties and other violations of law related to Reata’s agreement to be acquired by Biogen Inc. Under the terms of the agreement, Reata shareholders will receive $172.50 per share in cash.

Join This Action

First Name*

Last Name*

Email Address*

Mailing Address*

City*

State/Province*

Zip/Postal Code*

Phone*

Number of Shares Purchased

Date(s) Shares Purchased

Purchase Price Per Share

Number of Shares Sold

Date(s) Shares Sold

Sale Price Per Share

Comments

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Select files

By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Rigrodsky Law, P.A., retain Rigrodsky Law, P.A. to bring a lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 09/21/2023

X Code

* Indicates a required field.